May 16, 2019 07:14 AM EDTUpdated 12:09 PM
R&D

Gink­go BioWorks picks up an­tibi­otics ef­fort with Roche where Warp Dri­ve Bio left off

Amber Tong

When Rev­o­lu­tion Med­i­cines ab­sorbed fel­low Third Rock start­up Warp Dri­ve Bio in­to its op­er­a­tions last Oc­to­ber — then new­ly tran­si­tioned from an­ti­fun­gal to on­col­o­gy — the ex­ec …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times